Larry Neuman
Internal Medicine · New York, NYNPI 1992907539
Payments from drug & device makers
Across 2,188 payments — averaging $208.86 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$216K
- Axsome Therapeutics, Inc.$62K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$48K
- Gilead$34K
- CMP Pharma, Inc.$27K
- Sumitomo Pharma America, Inc.$15K
- plus $55K from 54 others
What the payments were for
- Consulting fees$32,1057%
- Speaking & faculty fees$350,35477%
- Travel & lodging$16,5914%
- Food & beverage$57,82213%
- Education$1060%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$456,977 in reported general payments places this provider in the 95th percentile of 9,771 internal medicine providers in New York.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Hydrocortisone Butyrate | 1,646 | $1,581,419 |
| ProliaDenosumab | 357 | $573,171 |
| VraylarCariprazine Hcl | 309 | $457,153 |
| UbrelvyUbrogepant | 262 | $419,982 |
| Diclofenac Potassium | 482 | $385,331 |
| CreonLipase/Protease/Amylase | 135 | $330,848 |
| OzempicSemaglutide | 312 | $288,600 |
| Budesonide ErBudesonide | 218 | $286,438 |
| Omeprazole-Sodium BicarbonateOmeprazole/Sodium Bicarbonate | 448 | $242,792 |
| LinzessLinaclotide | 379 | $232,647 |
| MeloxicamMeloxicam, Submicronized | 522 | $205,031 |
| Diclofenac Sodium | 772 | $170,961 |
| QuliptaAtogepant | 161 | $170,039 |
| Chlorzoxazone | 248 | $155,458 |
| GemtesaVibegron | 262 | $131,594 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| AbbVieVraylar, Ubrelvy, Creon, Linzess, Qulipta | $216,456 | $1,610,6681,246 claims |
| AmgenProlia | $1,257 | $573,171357 claims |
| Novo NordiskOzempic | $821 | $288,600312 claims |
| MerckJanumet, Januvia | $205 | $133,766155 claims |
| Sumitomo Pharma America, Inc.Gemtesa | $14,567 | $131,594262 claims |
| AstraZenecaFarxiga | $4,895 | $127,607177 claims |
| Axsome Therapeutics, Inc.Auvelity | $61,913 | $123,713116 claims |
| GileadBiktarvy, Descovy | $33,709 | $118,21745 claims |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)Caplyta | $47,989 | $116,40367 claims |
| PfizerNurtec Odt | $764 | $89,15948 claims |
| Ardelyx, Inc.Ibsrela | $1,030 | $87,15650 claims |
| Boehringer IngelheimJardiance | $564 | $78,27264 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 9,771 internal medicine providers in New York.
Other internal medicine in New York
- Helena YuNew York$50.9M
- Neha KordeNew York$21.2M
- Karen AutioNew York$18.5M
- Ingo MellinghoffNew York$16.1M
- Gopakumar IyerNew York$12.4M
- Sally LauNew York$8.4M
- Maria RubinsteinNew York$6.3M
- Dana RathkopfNew York$6M
- Eytan SteinNew York$5.8M
- James GreenwaldNew York$4.9M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.